3 million additional contracts for Pfizer vaccine… 20 million additional contracts for NovaVax vaccine
The Korea Centers for Disease Control and Prevention (Director Eun-kyung Jeong) announced that it would contract an additional 23 million COVID-19 vaccines for a more stable vaccine supply in the first half of the year.
The government signed an additional purchase contract for 3 million Pfizer vaccines (6 million doses) on the 15th, and advanced the start of supply from the first 3 quarter to the first quarter (end of March). In addition, a contract is signed for 20 million doses (40 million doses) of NovaVax vaccine, which has been discussing purchase contracts so far.
As uncertainties in the production and supply of COVID-19 vaccines are increasing around the world, the volume of vaccines in the first half is particularly limited.
In order to prepare for the various uncertainties in the supply and demand of these vaccines, the government purchased an additional 3 million people (6 million doses) in addition to 10 million Pfizer vaccines (20 million doses) contracted last year, resulting in a total of 13 million people (26 million doses). Pfizer made a contract to purchase a vaccine.
In addition, Pfizer vaccine was initially scheduled to be introduced from the third quarter, but according to the results of early supply negotiations with pharmaceutical companies, 500,000 people (1 million doses) in the first quarter (end of March) and 3 million people (6 million doses) in the second quarter. Will be supplied.
Currently, the Pfizer vaccine is undergoing approval review by the Ministry of Food and Drug Safety and will be vaccinated from April when the national shipment approval for the vaccine introduced in late March is completed.
Also, on the 16th, the Korea Centers for Disease Control and Prevention (KCDC) held a contract to supply a vaccine for COVID-19 NovaVax with SK Bioscience (CEO Jae-yong Ahn), and signed a pre-purchase contract for 20 million people (40 million doses).
Chairman James Young will participate in the contract signing ceremony through video connection with NovaVax headquarters (USA), and will discuss cooperation measures for the production and supply of Corona 19 vaccines between the Korea Centers for Disease Control and Prevention, NovaVax, and SK Bioscience.
Commissioner Eun-kyung Chung said, “In a situation where there is a lot of uncertainty in the supply of vaccines around the world, we will contribute to a stable supply and supply through the early introduction of NovaVax vaccine and Pfizer vaccine that can be produced and supplied in Korea.” By adding (40 million doses), we have secured a total of 79 million vaccines (152 million doses) so far, and we plan to make efforts for early supply and rapid vaccination in the future.”
Copyright © Medical News Unauthorized reproduction and redistribution prohibited